hemoglobin glutamer 250
Biologicalexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00301535)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Hemoglobin HbASupplementation
HBB supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109162 ↗
- ChEMBLCHEMBL2108603 ↗
Also known as
- hboc 201
- hboc-201
- hboc-201
- hboc-201
- hemoglobin-based oxygen carrier-201
- hemoglobin glutamer
- hemoglobin glutamer 250
- hemoglobin glutamer-250
- hemoglobin glutamer-250 (bovine)
- hemoglobin glutamer (bovine)
- hemopure
- hemopure
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02934282 | N/A | Oct 4, 2016 | University of Miami |
| NCT02684474 | N/A | Feb 10, 2016 | Johns Hopkins University |
| NCT01881503 | N/A | Oct 1, 2013 | Englewood Hospital and Medical Center, HBO2 THERAPEUTICS |
| NCT00300040 | Phase 2 | May 1, 2006 | Biopure Corporation |
| NCT00301535 | Phase 2 | Feb 1, 2006 | Biopure Corporation |
| NCT03633604 | N/A | — | HBO2 THERAPEUTICS, University of Pittsburgh |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biopure Corporation | For profit | 2 | 2 | 1 | 2006 |
| HBO2 THERAPEUTICS | For profit | 2 | 0 | 1 | 2013 |
| Englewood Hospital and Medical Center | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | — |
6 organizations
Page 1 / 1